Home › Cancer (all types) › NCT05181826

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

2.1.1 Age 18 years or older.

2.1.2 A diagnosis of cancer, cancer remission, benign disease (benign tumor, diabetes, liver cirrhosis, chronic hepatitis B or hepatitis C virus infection, Chronic obstructive pulmonary disease, etc.) or apparently healthy volunteers. .

Exclusion Criteria:

2.2.1 Patients that are unwilling or unable to sign the Informed Consent Form will be excluded.

2.2.2 Approximately 50 mL of blood will be drawn from participants within an 8-week period under this protocol. Patients that have already given 50 mL of blood within this time frame will be excluded.

About the study

To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.

What is being tested

• Multi-analyte Blood Test (diagnostic test)

Sponsor: Helio Genomics · Participants: 1,200 · Started: May 21, 2019

Contact the study team

• Clinical Operations Manager · Phone: 6263500537

Official record on ClinicalTrials.gov — NCT05181826

Locations in the U.S.

Conditions

• Cancer (all types)
• Cirrhosis
• Hepatitis B
• Hepatitis C
• Diabetes
• COPD

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.